These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 36671250)
1. Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations. Marino A; Stracquadanio S; Campanella E; Munafò A; Gussio M; Ceccarelli M; Bernardini R; Nunnari G; Cacopardo B Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671250 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives. Bavaro DF; Belati A; Diella L; Stufano M; Romanelli F; Scalone L; Stolfa S; Ronga L; Maurmo L; Dell'Aera M; Mosca A; Dalfino L; Grasso S; Saracino A Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34072342 [TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
4. Activity of Cefiderocol Against Iregui A; Khan Z; Landman D; Quale J Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915 [TBL] [Abstract][Full Text] [Related]
5. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821 [TBL] [Abstract][Full Text] [Related]
6. Cefiderocol (Fetroja) as a Treatment for Hospital-Acquired Pneumonia. Plaisance CJ; Borne GE; Daniel CP; Wagner MJ; Shelvan A; Mathew J; Ahmadzadeh S; Paladini A; Varrassi G; Shekoohi S; Kaye AD Cureus; 2024 Jan; 16(1):e52230. PubMed ID: 38352089 [TBL] [Abstract][Full Text] [Related]
7. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675 [TBL] [Abstract][Full Text] [Related]
8. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196 [TBL] [Abstract][Full Text] [Related]
9. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria. Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576 [TBL] [Abstract][Full Text] [Related]
10. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273 [TBL] [Abstract][Full Text] [Related]
11. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
14. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Giacobbe DR; Ciacco E; Girmenia C; Pea F; Rossolini GM; Sotgiu G; Tascini C; Tumbarello M; Viale P; Bassetti M; Infect Drug Resist; 2020; 13():4697-4711. PubMed ID: 33402840 [TBL] [Abstract][Full Text] [Related]
15. An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Gatti M; Viaggi B; Rossolini GM; Pea F; Viale P Antibiotics (Basel); 2021 Dec; 11(1):. PubMed ID: 35052910 [TBL] [Abstract][Full Text] [Related]
16. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]